Medical NewsCancer patients receiving drugs to lower the risk of anaemia...
Published Tuesday 01 December 2009
Chemotherapy can result in insomnia
Insomnia occurs in approximately three-quarters of cancer patients who have...
Published Tuesday 01 December 2009
Osteoarthritis risk increased by high exercise levels
Men and women in middle age who exercise on a...
Published Monday 30 November 2009
Cancer genome changes increase cervical cancer relapse risk
Patients with cervical cancer are three to four times more...
Published Sunday 29 November 2009
More Medical News
Opioids and Pain
Please note- The EPG Opioids and Pain Knowledge Centre is for Doctors and other Healthcare Professionals.
The Pain in Europe survey1 revealed the truly shocking nature, prevalence and impact of chronic pain in Europe and its devastating human, economic and social impact.
Types of chronic pain include both cancer and non-cancer pain. Pain is the single most common reason for consultation with a general practitioner and is the most frequent symptom in hospital practice.2 Pain is also an individual experience and can be measured in a number of ways.
In Europe, the main activities affected by pain are exercising, sleeping, lifting, walking, carrying out chores, having sexual relations and working outside the home.1
Chronic pain management can be managed through opioid therapy. However, before initiating opioid therapy, it is important that all patients undergo a thorough physical, psychological and functional examination, to ensure the management regimen is appropriate.
It is important to maintain frequent interaction between the doctor, healthcare team and patient on an ongoing basis to effectively monitor the dosage, side effects and funtional outcomes.
Other drugs that are widely used to control pain include paracetamol and NSAID's.
Enter the Opioids and Pain Knowledge Centre
What’s in the Opioids and Pain Knowledge Centre?
- Prevalence of chronic pain
- Types of chronic pain
- Pain measurement
- Effects
- Initiating opioid therapy
- Monitoring
- Medication
- Additional and complementary therapy
- Opioids
- History
- Classification
- Why opioids?
- Administration
- Use in palliative care
- Adverse effects
- Misconceptions
- Web links
- Downloads
- Multimedia
References:
1. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10:287-333.
2. MIMS Handbook of pain management. London: Haymarket Medical Imprint; 2006.
-
Naloxone - 48.28%
... partial reversal of CNS and especially respiratory depression, caused by natural or synthetic opioids . • Diagnosis of suspected acute opioid overdose or intoxication. • Complete or partial reversal of respiratory and other CNS depression in the neonate whose mothers have received opioids ... -
Effentora 100, 200, 400, 600 and 800 micrograms buccal tablets - 17.14%
... with cancer who are already receiving maintenance opioid therapy for chronic cancer pain . BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral ... -
Methadone 10mg/ml - 16.61%
Methadone injection may be used in the management of opioid dependence; as an analgesic for moderate to severe pain as an alternative to morphine. Opioid dependence: The use of injectable methadone for this indication must be initiated by physicians with adequate expertise and experience in ... -
Osmanil 75 micrograms/h transdermal patch (Winthrop) - 15.97%
The product is indicated in severe chronic pain which can be adequately managed only with opioid analgesics ... -
Abstral Sublingual Tablets - 15.97%
Management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Breakthrough pain is a transient exacerbation of otherwise controlled chronic background pain ... -
SUBOXONE Sublingual Tablets - 15.97%
Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for ...